Joey received his PhD in Computer Science from the University of Colorado focused on the intersection of AI and cancer genomics where he developed Arpeggio's founding IP. After training at Merck and FORMA Therapeutics, he started Arpeggio with Laura & Tim. He was awarded Forbes 30-under-30 in 2019.
Joey Azofeifa, PhD
CEO & co-founder
Following his BS in Biochemistry and Computer Science, Nick performed research in the Falke & Clauset groups spanning the gap between machine learning and biology. At Arpeggio, Nick works on automated transcriptomic drug screen and analysis pipelines.
Ardeshir received his PhD from UNC Chapel Hill on molecular dynamics of diseased proteins. He went to do a postdoctoral fellowship at AstraZeneca and become an investigator at Novartis. Ardeshir leads our computational chemistry, bridging the gab between AI, biology, and medicinal chemistry.
Ardeshir Goliaei, PhD
Following his BA in Cell & Molecular Biology from CU-Boulder, Cole performed research at the Anshutz Medical Campus in anesthetic drug discovery. At Arpeggio, Cole works at the interface of assay development, automations, and drug screening.
Eric is a drug discovery and development executive with more than 20 years of experience leading preclinical and translational teams at Pfizer, Ignyta, Plexxikon and Kinnate Biopharma. His research and mission is in developing the next generation of inhibitors to combat drug resistance in cancer.
Eric Martin, PhD
Following her BA in Psychology from UNL, Laura went on to found multiple companies in the makers space. She also consulted for many startups, focused on rapid growth potential. After founding Arpeggio, Laura leads everything from corporate structure, legal, HR, and project management.
COO & co-founder
After receiving his BS in Biochemistry & Biophysics from RPI, Casey worked as an automations engineer at AmeriDrug Labs, Pfizer Oncology and, most recently, Hamilton Robotics. At Arpeggio, Casey manages our automated drug transcriptomic screenining platform.
Tim received his PhD in Molecular Biology from the University of Colorado focused mechanisms of eukaryotic transcription. After a postdoctoral fellowship at Harvard Med, Tim founded Arpeggio to lead and industrialize our transcriptomic drug screen.
Tim Read, PhD
CTO & co-founder
Jenna focused her PhD work on the mechanisms of RNA Pol II mediated transcription with Dylan Taatjes and collaborated with Syros Pharmaceuticals on a novel CDK7 inhibitor. At Arpeggio, Jenna focuses on target discovery and validation for transcriptional addiction mechanisms in cancer.
Jenna Rimel, PhD
From Harvard Medical School, Martek Biosciences, and the University of Colorado, Dave has over 20 years of experience running and managing molecular biology labs. At Arpeggio, Dave connects lab operations to our drug discovery initiatives.
Lab Operations Manager
Bill has led IP at companies such as Advanced Liquid Logic, Illumina and Grail. At Arpeggio, Bill is critical helping define our patent strategy and portfolio around both our platform as well as our novel chemical entities.
From 2002 to 2016, Joe was the president & CEO of KBI Biopharma, growing the company from just 10 employees to over a thousand. Currently he is president & CEO of Bioventure partners where he advises early stage companies like Arpeggio.
John started his career at BMS where he was a group leader of discovery chemistry. Currently, John advices early stage companies on their medicinal chemistry design and interfaces with CROs to drive fast and accurate preclinical development.
John Dickson, PhD
Medicinal Chemistry Advisor
Dave started his career at GSK where he was VP of Biological Platform Technology and Science and more recently VP of Research Operations at Precision BioSciences. At Arpeggio, Dave advises on systems biology and our automated drug screening platform.
Dave Morris, PhD
Platform Automation Advisor